Lactated Ringer vs Normal Saline Solution During Sickle Cell Vaso-Occlusive Episodes.

IF 22.5 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL
Augusta K Alwang, Anica C Law, Elizabeth S Klings, Robyn T Cohen, Nicholas A Bosch
{"title":"Lactated Ringer vs Normal Saline Solution During Sickle Cell Vaso-Occlusive Episodes.","authors":"Augusta K Alwang, Anica C Law, Elizabeth S Klings, Robyn T Cohen, Nicholas A Bosch","doi":"10.1001/jamainternmed.2024.4428","DOIUrl":null,"url":null,"abstract":"<p><strong>Importance: </strong>Sickle cell disease (SCD), a clinically heterogenous genetic hemoglobinopathy, is characterized by painful vaso-occlusive episodes (VOEs) that can require hospitalization. Patients admitted with VOEs are often initially resuscitated with normal saline (NS) to improve concurrent hypovolemia, despite preclinical evidence that NS may promote erythrocyte sickling. The comparative effectiveness of alternative volume-expanding fluids (eg, lactated Ringer [LR]) for resuscitation during VOEs is unclear.</p><p><strong>Objective: </strong>To compare the effectiveness of LR to NS fluid resuscitation in patients with SCD and VOEs.</p><p><strong>Design, setting, and participants: </strong>This multicenter cohort study and target trial emulation included inpatient adults with SCD VOEs who received either LR or NS on hospital day 1. The Premier PINC AI database (2016-2022), a multicenter clinical database including approximately 25% of US hospitalizations was used. The analysis took place between October 6, 2023, and June 20, 2024.</p><p><strong>Exposure: </strong>Receipt of LR (intervention) or NS (control) on hospital day 1.</p><p><strong>Main outcome and measures: </strong>The primary outcome was hospital-free days (HFDs) by day 30. Targeted maximum likelihood estimation was used to calculate marginal effect estimates. Heterogeneity of treatment effect was explored in subgroups.</p><p><strong>Results: </strong>A total of 55 574 patient encounters where LR (n = 3495) or NS (n = 52 079) was administered on hospital day 1 were included; the median (IQR) age was 30 (25-37) years. Patients who received LR had more HFDs compared with those who received NS (marginal mean difference, 0.4; 95% CI, 0.1-0.6 days). Patients who received LR also had shorter hospital lengths of stay (marginal mean difference, -0.4; 95% CI, -0.7 to -0.1 days) and lower risk of 30-day readmission (marginal risk difference, -5.8%; 95% CI, -9.8% to -1.8%). Differences in HFDs between LR and NS were heterogenous based on fluid volume received: among patients who received less than 2 L, there was no difference in LR vs NS; among those who received 2 or more L, LR was superior to NS.</p><p><strong>Conclusion and relevance: </strong>This cohort study found that, compared with NS, LR had a small but significant improvement in HFDs and secondary outcomes including 30-day readmission. These results suggest that, among patients with VOEs in whom clinicians plan to give volume resuscitation fluids on hospital admission, LR should be preferred over NS.</p>","PeriodicalId":14714,"journal":{"name":"JAMA Internal Medicine","volume":" ","pages":"1365-1372"},"PeriodicalIF":22.5000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11385329/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAMA Internal Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1001/jamainternmed.2024.4428","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Importance: Sickle cell disease (SCD), a clinically heterogenous genetic hemoglobinopathy, is characterized by painful vaso-occlusive episodes (VOEs) that can require hospitalization. Patients admitted with VOEs are often initially resuscitated with normal saline (NS) to improve concurrent hypovolemia, despite preclinical evidence that NS may promote erythrocyte sickling. The comparative effectiveness of alternative volume-expanding fluids (eg, lactated Ringer [LR]) for resuscitation during VOEs is unclear.

Objective: To compare the effectiveness of LR to NS fluid resuscitation in patients with SCD and VOEs.

Design, setting, and participants: This multicenter cohort study and target trial emulation included inpatient adults with SCD VOEs who received either LR or NS on hospital day 1. The Premier PINC AI database (2016-2022), a multicenter clinical database including approximately 25% of US hospitalizations was used. The analysis took place between October 6, 2023, and June 20, 2024.

Exposure: Receipt of LR (intervention) or NS (control) on hospital day 1.

Main outcome and measures: The primary outcome was hospital-free days (HFDs) by day 30. Targeted maximum likelihood estimation was used to calculate marginal effect estimates. Heterogeneity of treatment effect was explored in subgroups.

Results: A total of 55 574 patient encounters where LR (n = 3495) or NS (n = 52 079) was administered on hospital day 1 were included; the median (IQR) age was 30 (25-37) years. Patients who received LR had more HFDs compared with those who received NS (marginal mean difference, 0.4; 95% CI, 0.1-0.6 days). Patients who received LR also had shorter hospital lengths of stay (marginal mean difference, -0.4; 95% CI, -0.7 to -0.1 days) and lower risk of 30-day readmission (marginal risk difference, -5.8%; 95% CI, -9.8% to -1.8%). Differences in HFDs between LR and NS were heterogenous based on fluid volume received: among patients who received less than 2 L, there was no difference in LR vs NS; among those who received 2 or more L, LR was superior to NS.

Conclusion and relevance: This cohort study found that, compared with NS, LR had a small but significant improvement in HFDs and secondary outcomes including 30-day readmission. These results suggest that, among patients with VOEs in whom clinicians plan to give volume resuscitation fluids on hospital admission, LR should be preferred over NS.

镰状细胞性血管闭塞症发作时的乳酸林格液与正常生理盐水的对比
重要性:镰状细胞病(SCD)是一种临床上异质性遗传血红蛋白病,其特点是血管闭塞性发作(VOE)疼痛难忍,需要住院治疗。尽管有临床前证据表明,生理盐水可能会促进红细胞镰状化,但因血管闭塞发作而入院的患者最初通常会使用生理盐水(NS)进行复苏,以改善并发的低血容量。目前还不清楚在 VOE 期间使用其他扩容液(如乳酸林格液 [LR])进行复苏的效果比较:比较 LR 和 NS 液体复苏对 SCD 和 VOE 患者的效果:这项多中心队列研究和目标试验模拟纳入了在住院第 1 天接受 LR 或 NS 的 SCD VOEs 住院成人患者。研究使用的是 Premier PINC AI 数据库(2016-2022 年),这是一个多中心临床数据库,包含了约 25% 的美国住院病例。分析时间为 2023 年 10 月 6 日至 2024 年 6 月 20 日:主要结果和测量指标:主要结果是第 30 天时的无住院日(HFDs)。采用目标最大似然估计法计算边际效应估计值。在分组中探讨了治疗效果的异质性:共纳入了 55 574 例在住院第 1 天接受 LR(n = 3495)或 NS(n = 52 079)治疗的患者;中位数(IQR)年龄为 30(25-37)岁。与接受 NS 治疗的患者相比,接受 LR 治疗的患者的高频分解时间更长(边际平均差异为 0.4 天;95% CI 为 0.1-0.6 天)。接受 LR 治疗的患者住院时间更短(边际平均差异为-0.4;95% CI 为-0.7--0.1 天),30 天再入院风险更低(边际风险差异为-5.8%;95% CI 为-9.8%--1.8%)。根据输液量的不同,LR 和 NS 之间的高密度脂蛋白胆固醇血症差异也不同:在输液量少于 2 升的患者中,LR 和 NS 之间没有差异;在输液量大于等于 2 升的患者中,LR 优于 NS:这项队列研究发现,与 NS 相比,LR 对高密度脂蛋白胆固醇和次要结果(包括 30 天再入院)有微小但显著的改善。这些结果表明,对于临床医生计划在患者入院时给予容量复苏液的 VOE 患者,LR 比 NS 更受青睐。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
JAMA Internal Medicine
JAMA Internal Medicine MEDICINE, GENERAL & INTERNAL-
CiteScore
43.50
自引率
1.30%
发文量
371
期刊介绍: JAMA Internal Medicine is an international, peer-reviewed journal committed to advancing the field of internal medicine worldwide. With a focus on four core priorities—clinical relevance, clinical practice change, credibility, and effective communication—the journal aims to provide indispensable and trustworthy peer-reviewed evidence. Catering to academics, clinicians, educators, researchers, and trainees across the entire spectrum of internal medicine, including general internal medicine and subspecialties, JAMA Internal Medicine publishes innovative and clinically relevant research. The journal strives to deliver stimulating articles that educate and inform readers with the latest research findings, driving positive change in healthcare systems and patient care delivery. As a member of the JAMA Network, a consortium of peer-reviewed medical publications, JAMA Internal Medicine plays a pivotal role in shaping the discourse and advancing patient care in internal medicine.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信